Prediction market event contracts tied to sensitive clinical drug trials and Food and Drug Administration regulatory approvals have officially drawn the intense scrutiny of Capitol Hill. According to a congressional letter obtained first by CNBC, two prominent Democratic senators are demanding answers from the executive branch regarding the potential hazards these financial products pose to public health, scientific integrity, and regulatory oversight.
Sen. Angela Alsobrooks of Maryland and Sen. Ron Wyden of Oregon voiced their deep concerns in a joint Wednesday letter addressed to Department of Health and Human Services Secretary Robert F. Kennedy Jr. In their communication, the lawmakers formally requested detailed information regarding the measures HHS has enacted to mitigate the distinct systemic risks that arise when financial speculation intersects with pharmaceutical development and federal drug approvals.
The introduction of event contracts allowing everyday traders and speculators to wager money on the success or failure of experimental medical treatments has sparked widespread alarm across the healthcare sector. In their letter, Alsobrooks and Wyden pulled no punches regarding the potential downstream consequences of gamifying medical science.
"Allowing individuals to bet on the success of these trials and drugs undermines the scientific process, creates perverse incentives for researchers, harms trial participants, and could lead to dangerous medical outcomes for untold numbers of Americans," the senators wrote in the correspondence.
The concerns raised by Alsobrooks and Wyden closely mirror warnings previously sounded by healthcare professionals, clinical researchers, and bioethicists. Critics of the practice have repeatedly argued that introducing financial wagers into the clinical trial ecosystem could fundamentally alter patient psychology and decision-making. Individuals weighing whether to volunteer as participants in potentially lifesaving or life-altering medical trials might be influenced—or see the sanctity of the informed consent process compromised—by the presence of active public betting markets surrounding the trial’s outcome.
Furthermore, the lawmakers highlighted severe potential insider trading risks. Regulatory personnel, clinical investigators, and pharmaceutical researchers frequently possess access to sensitive, nonpublic information regarding the trajectory, efficacy, and safety profiles of drugs under review. The existence of liquid prediction markets creates a tempting avenue for individuals with privileged knowledge to monetize insider data illicitly, evading traditional regulatory surveillance designed for standard equities and derivatives.
Communication request
To better understand the scope of the issue and determine whether federal employees are engaging in speculative trading related to their official duties, the senators outlined a sweeping series of oversight demands.
Alsobrooks and Wyden requested that HHS provide all internal communications regarding staff participation in prediction markets tied to matters governed by the department. Additionally, the lawmakers demanded copies of all correspondence between the department and prediction market platforms themselves, as well as communications with the Commodity Futures Trading Commission, the federal regulator tasked with overseeing event contracts. They also asked for any internal analyses conducted by HHS agencies regarding the potential public health and regulatory impacts of these markets.
"HHS, FDA, and the National Institutes of Health must uphold the integrity of the drug development process and maintain public trust in the public health by putting essential guardrails in place to prevent individuals profiting on the success and approval of drugs that the American people depend on," Alsobrooks and Wyden emphasized in their letter.
The controversy centers on innovative financial products offered by leading prediction market platforms, including Kalshi and Polymarket. While Kalshi operates as a regulated exchange within the United States, Polymarket offers similar event contracts through its international exchange, which is not regulated domestically.
When Kalshi formally launched its suite of biotech and pharmaceutical prediction markets in July, the platform defended its offerings by asserting that comprehensive risk-mitigation measures had been embedded into the system. Company executives pointed out that Kalshi restricted its event contracts exclusively to late-stage clinical trials, explicitly avoiding early-stage exploratory research where safety risks and information volatility are significantly higher.
Moreover, Kalshi committed to listing contracts only after a specific clinical trial had successfully completed its patient enrollment phase. The platform also implemented advanced employee verification technology designed to monitor and restrict traders participating in the markets, aiming to block potential conflicts of interest.
At the time of the launch, Kalshi CEO Tarek Mansour defended the societal utility of the platform’s offerings in the pharmaceutical space.
"Drug development is one of the most important and most information-constrained industries on earth," Mansour said in July, addressing the rationale behind the product line. "The data that determines which drugs advance and which don’t is largely locked away from the people who need it most. Surfacing information is what Kalshi is for, and we are committed to doing it right."
Kalshi representatives also pushed back against the notion that prediction markets introduce unique ethical dilemmas not already present in traditional financial systems. The company noted that institutional and retail investors routinely buy and sell shares of publicly traded biotechnology and pharmaceutical companies that are actively awaiting major FDA regulatory decisions and clinical trial readouts.
"The hypothetical concerns of the Senators apply equally to the equities market, which appears to be left out of their letter," Kalshi spokesperson Jack Such told CNBC in response to the inquiry. "The only difference is that the size—and incentive for bad activity—is significantly higher in the equities market than it is on Kalshi."
As the congressional inquiry lands on the desk of HHS leadership, broader questions regarding the regulatory perimeter of event contracts continue to ripple through Washington. Representatives for Polymarket and the Department of Health and Human Services did not immediately respond to repeated requests for comment from CNBC regarding the senators’ letter and the ongoing debate over pharmaceutical forecasting.

Comments (0)